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ABSTRACT 
 
Objective. Because an increasing number of clinical trials evaluating disease modifying anti-
rheumatic drugs in rheumatoid arthritis (RA) emphasize radiographic outcomes as a primary 
outcome, using a reproducible radiographic measure should be placed at a premium. We 
aimed to evaluate the reporting of radiographic methods in randomized trials assessing 
radiographic outcomes in RA. 
Methods. We searched MEDLINE for randomized controlled trials assessing radiographic 
outcomes published between January 1994 and December 2005 in general medical and 
specialty journals with a high impact factor. One reader extracted data (radiographic 
acquisition, assessment and reproducibility) using a standardized form. 
Results. A total of 46 reports were included in the analysis. The mean (SD) methodological 
quality scores on the Jadad scale (range 0-5) and the Delphi list (0-9) were 2.9 (1.2) and 6.4 
(1.3), respectively. Use of a standardized procedure for the acquisition of the radiographs was 
reported in 2 articles (4.3%). Two reports (4.3%) indicated that the quality of the radiographs 
was evaluated. In 65.2% of the reports, 2 or more radiographic scores were used. Reporting of 
radiographic assessment was well detailed for number of readers (91.3%), information on 
readers (71.7%), blinding (91.4%) and how films were viewed (74.0%). The reproducibility 
of the reading was reported in 39.1% of the articles. 
Conclusion. Our results highlight that the reporting of results of randomized controlled trials 
of radiographic outcomes in RA shows great variability in radiographic scores used and that 
reporting of radiographic methods could be improved upon, especially the acquisition 
procedure and the reproducibility of the reading.  
Key words: rheumatoid arthritis, randomized controlled trials, reproducibility, radiographic 
acquisition, radiographic assessment 
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Rheumatoid arthritis (RA) is the most common chronic inflammatory joint disease 
andis responsible for symptomatic manifestations (e.g., functional status, pain) and structural 
damage (i.e., damage of the articular cartilage and bone) (1). The use of disease-modifying 
anti-rheumatic drugs has increased for RA (2). Assessing such treatments requires the 
measurement of structural outcomes in randomized controlled trials to demonstrate a 
reduction or a retardation of disease progression.  
Radiography provides an objective measure of the extent of anatomical joint damage. 
It  can be used to assess the severity of the structural destruction, to follow the course of the 
disease and to establish effects of treatment (3). This highly accepted technique is widely 
available and provides a permanent record of the structural image, allowing for comparison 
over time and rereading if necessary (4, 5). The assessment of radiographic outcomes for 
evaluating drug efficacy was recommended for the management of RA in controlled trials (6, 
7) and the radiographic outcome is often used as a primary endpoint for assessing structural 
severity (8).  
The reproducibility (i.e., the extent to which repeated measurements on the same 
subject yield the same results) is one of the prerequisites for a primary outcome (9-11). With 
radiography, measurements can be biased and their precision compromised by 2 well-
identified sources of variability -- image acquisition and assessment -- which can be a serious 
limitation in its use. The image variability due to differences in acquisition processes is a 
major concern. Because many parameters can affect the appearance of the radiographs (i.e., 
positioning for radiographs, film exposure and resolution, reproducibility), standardization of 
the acquisition procedure is needed (12, 13). Similarly, radiographic assessment could be 
influenced by many known parameters (e.g., the scoring method, the number of readers, films 
grouped by patient or not, films chronologically scored or not) (14). 
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Evaluating the reproducibility of an outcome measure theoretically supposes a detailed 
reporting of the methods used to measure it. The CONSORT (Consolidated Standards of 
Reporting Trials) statement has recommended the reporting of methods used “to enhance the 
quality of measurements”, especially when considering the primary outcome (15), including 
how the outcome was measured and what steps were used to increase the reliability. 
The purpose of this study was to evaluate the reporting of radiographic methods in 
randomized controlled trials assessing radiographic outcomes in RA. We investigated 
particularly radiographic acquisition, radiographic assessment and how the reproducibility 
was determined.  
 5 
MATERIALS AND METHODS 
 
Search strategy for identification of studies 
 
The search method has been detailed elsewhere (16). Briefly, we searched MEDLINE and the 
Cochrane Central Register of Controlled Trials for randomized controlled trials assessing 
radiographic outcomes in RA published between January 1994 and December 2005 in general 
medical and specialty journals with a high impact factor (Appendix A). We chose these 
journals because a high impact factor is a good predictor of high methodological quality of 
journal articles (17) and because our goal was not to be exhaustive but, rather, to raise 
awareness of the reporting of radiographic assessment and acquisition. Potentially relevant 
articles were selected on the basis of the title, abstract and keywords by one reader (GB) using 
the following criteria: study population of adults aged 18 years or older, randomized 
controlled trial, and presence of at least 1 radiographic outcome evaluated by scheduled 
radiography. When duplicate publications of a trial existed, only the main publication was 
included (i.e., when a report of the same trial appeared twice or more, the report of the 
principal analysis planned by the protocol was selected). Reports of extended follow-up trials, 
analyses of multiple trials and subgroup analyses were excluded. When the abstract indicated 
that the article might be relevant, the entire paper was obtained. 
 
Data extraction 
 
One author (GB) extracted all the data using a standardized form. From each article, data were 
obtained for the following:  
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(I) Characteristics of the included articles. Data were searched for number of centers, sample 
size, and methodological quality scores (Jadad scale (18) and the Delphi list (19)). The 
reviewer also determined whether the radiographic outcome was clearly defined as the 
primary endpoint. 
(II) Radiographic acquisition. The reviewer extracted data on regions assessed (e.g., hand, 
feet), number of radiographic sessions, time between baseline session and the last session, and 
time between 2 radiographic sessions. The reviewer checked whether methods used to take 
the radiographs were detailed: radiographic view (e.g., dorsovolar, anteroposterior), use of a 
standardized procedure to improve positioning, description of the image quality (film 
exposure and use of resolution films), and use of digitized image or not. 
(III) Radiographic assessment. The reviewer collected data on which score was used for 
primary and secondary radiographic analysis and determined whether information was 
included on the reader’s experience (e.g., it was explicitly stated that radiographs were read 
by a well-known expert), background (e.g., radiologist) and identity (e.g., initials reported); 
and whether there were multiple observers (i.e., methods of consensus to obtain a single score 
described when appropriate). The reviewer also checked whether the assessment of the 
radiographs was blinded (i.e., to treatment assignment or patient identity and clinical data). 
He also determined how films were read (paired reading with chronological or random order). 
(IV) Reproducibility. The reviewer recorded whether intra- and inter-reader reproducibility 
was evaluated and how. 
 
Analysis 
 
Categorical variables were described with frequencies and percentages and quantitative 
variables with means (SD) or medians [minimum, maximum]. Two ancillary analyses were 
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also performed. The first describes characteristics of the radiographic assessment in reports 
published before 2000 versus reports published in 2000 and later and the second compares 
reports with radiographic outcome defined as a primary endpoint and reports with a 
nonradiographic primary outcome. All data analyses involved use of SAS for Windows, 
Release 9.1 (SAS Institute, Cary, NC).  
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RESULTS 
 
Characteristics of the included articles 
 
The search strategy generated 1004 citations. Forty-six studies were relevant according to the 
title, abstract, and complete retrieval of the article (figure 1). Detailed references of the 
selected articles are listed in appendix B. 
Of the reports, 40 (87.0%) concerned multicenter studies. The median sample size of 
the studies was 183 [20, 1446] patients. The mean (SD) methodological quality scores were 
2.8 (1.0) for the Jadad scale and 6.5 (1.3) for the Delphi list. The radiographic outcome was 
clearly defined as the primary endpoint in 26 reports (56.5%). 
 
Radiographic acquisition 
 
Both joints of hand and feet were the most frequently assessed areas (75.0%) (table 1). In 
many reports (n=20, 43.5%), 2 radiographs (included baseline radiographs) were obtained 
(table 1). The median time between the baseline session and the last session was 12 months 
[5.5, 48 months] and the median time between 2 sessions was 53 weeks [24, 104 weeks]. 
The radiographic view (e.g., dorsovolar) was described in 11 reports (23.9%). Use of a 
standardized radiographic procedure for optimal positioning was reported in 2 articles (4.3%). 
The X-ray films were described as digitized in 3 reports (6.5%). The assessment of 
radiographic quality was reported in only 2 articles (4.3%) and details on film resolution (e.g., 
single emulsion film) were provided in 2 (4.3%) reports. 
 
Radiographic assessment 
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Radiographic score 
 
In 65.2% of the reports, 2 or more radiographic scores were used (table 2). Among scores 
combining erosions and joint space narrowing, the Sharp score and the Larsen score 
(including their modified versions) were the most represented methods (47.8% and 34.7%, 
respectively). 
 
Readers 
 
Information on reader(s) (i.e., readers’ experience in evaluating radiographs, readers’ 
background or identity) were described in 33 articles (71.7%). Readers’ experience, 
background and identity were reported in 17 (37.0%), 25 (54.3%), and 23 (50.0%) reports, 
respectively (table 3). 
In 4 reports (8.7%), the number of readers was impossible to determine. Radiographs 
were read by at least 2 readers in 30 reports (65.2%) and by a single reader in 12 (26.1%).  
Of the reports describing at least 2 readers, 22 described readers reading all the 
radiographs (61.1%) and 1 all the readers did not read all the radiographs (3.3%), and in 7 the 
reading was unclear (23.3%). When all the radiographs were read (n=22), a consensus method 
to produce a single radiographic score was described in 8 reports (consensus with the same 
readers for all disagreements [n=5], consensus for only important disagreements [n=2], or use 
of another method of measurement [n=1]); in 10 reports, the radiographic score used came 
from the mean score of the readers and from the lower score of the readers in 2 reports (in the 
2 remaining reports, it was unclear how a single score was obtained). 
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Blinding 
 
Masked assessment of radiographs was described in 43 (93.5%) reports (Table 3). Blinding 
was described to concern treatment assignment or patient identity (n=37, 86.0%) and clinical 
data (n=11, 23.9%); 4 articles reported that the assessor was blinded, with no other details 
given. 
 
Reading session 
 
In 12 articles (26.1%), no details were provided about the reading of the radiographs. When 
reading was described (73.9%), paired reading in random order and paired reading in 
chronological order were used in 18 (52.9%) and 15 (44.1%) articles, respectively. One article 
(2.9%) used both random and chronological paired reading.  
 
Reproducibility of the reading 
 
Reproducibility of the reading was described in 18 articles (39.1%). Intrareader 
reproducibility was reported in 9 (19.6) articles and inter-reader reproducibility in 13 (28.3) (4 
articles [8.7%] reported both intra- and inter-reader reproducibility). Five articles (10.8%) 
reported 2 reproducibility measures. Use of the intraclass correlation coefficient (n=8) and 
coefficient of correlation (n=7) and reporting the smallest detectable difference (n=6) were the 
most common methods used to assess reproducibility. Other methods were use of median 
with minimum and maximum (n=1). 
 
Ancillary analysis 
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When comparing reports with radiographic outcome defined as a primary endpoint versus 
other reports, we only found a major difference in the reporting of reproducibility (53.8% 
versus 20.0%) (table 3). 
 No difference was found in the reporting of radiographic assessment between reports 
published before 2000 and reports published in 2000 and later (table 3).  
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DISCUSSION 
 
Because an increasing number of clinical trials in RA emphasize radiographic 
outcome as a primary outcome, investigating the reporting of the radiographic methods is 
important. Our results show a great variability of the radiographic scores used and that 
radiographic assessment was better described than radiographic acquisition. Measures of 
reproducibility were reported in almost 40% of the assessed reports.  
 Reducing measurement error is an important objective, so use of a reproducible 
radiographic measure should be placed at a premium. Reporting reproducibility measures and 
describing methods of measurement are an essential step to confirm the validity of a measure 
(15). Controlling the reproducibility of a radiographic measurement concerns 2 steps: 
acquisition and assessment. 
 Although variability of acquisition can lead to measurement error (12, 13), only a few 
articles described radiographic acquisition in detail. The standardization of the acquisition is 
facilitated by centralized acquisition and entails training in radiographic acquisition and 
similar conditions of assessment (e.g., positioning for radiography (20)). Even if 
centralization of the acquisition is not always possible (e.g., because of multicenter studies or 
financial reasons), the training of radiologists could be centralized to decrease the variability. 
Radiographic assessment also depends on the technical quality of the radiographs, such as 
film exposure or resolution (21). So, evaluation of radiographic quality could be a control 
element that allows for limiting the number of nonassessable radiographs. 
When designing a trial, the choice of a radiographic score for assessing structural 
destruction can directly influence reproducibility (21, 22). When focusing on radiographic 
scores used in assessed reports, we found no consensus in assessment scores used, probably 
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because the radiographic score use has evolved over the years (21). However, in the last few 
years, the modified Sharp and Larsen scores seem to have been preferentially used (23).  
When considering other radiographic assessment characteristics, we noted that 
blindness was well respected and described in our study. Similarly, recommendations on 
reporting the number of observers and describing how to obtain a single measurement are 
followed (e.g., mean radiographic score from 2 assessors to decrease measurement error (24)). 
Specific training, as a calibration exercise, could be requested to come to an agreement when 
there are more than 1 reader. Some other parameters could be better described. For instance, 
experienced readers have been shown to have better agreement (22). A number of reports did 
not state in what order radiographs were assessed, even though this parameter can influence 
measurements (23, 25).  
 Almost 40% of the articles described the reproducibility of reading, even though 
reporting agreement between observers is essential to assessing the quality of observations 
(14, 26). If reproducibility was low or not assessed, then the use of radiographic outcomes as 
a primary endpoint may be questionable. Most of the methods reported, such use of as 
intraclass correlation coefficient or smallest detectable difference, were adapted for evaluating 
reproducibility. However, the use of the correlation coefficient as a measure of agreement was 
found in a surprising number of articles. Correlation coefficients measure the strength of an 
association, not the concordance, and thus should be avoided in this indication (27). 
Van der Heijde et al. give recommendations for improving the reporting of 
radiographic methods in studies of radiographic outcomes (14). Because the optimal 
interpretation of a radiograph also depends on conditions of acquisition, we suggest that the 
radiographic acquisition should be more detailed or referenced in reports. Such a description 
could entail whether a standardized protocol was followed, whether the technicians were 
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educated, whether the radiographs were digitized, whether the quality of films was assessed, 
which view was chosen and what kind of film was used.  
Our study is limited in that our search was restricted to articles published in high-
impact-factor journals. However, articles in low-impact-factor journals may have had the 
same or lower methodological quality. Second, we pooled phase II and III studies with those 
of a more epidemiological nature, even if they were also randomized controlled trials. The 
degree of conformance with regulatory requirements and, consequently, required details and 
rigor are probably more important for reporting phase II and phase III trials. Third, the 
radiographic outcome was not always defined as a primary endpoint in our selected studies. 
We could have presumed a more detailed description of the conditions of measurement if we 
considered only reports in which the radiographic outcome was the primary endpoint, but 
results were quite similar. We also decided to include all the studies in all the fields evaluated 
because the primary outcome has been shown to differ between protocols and reports of 
studies. In fact, Chan et al. demonstrated that primary outcome differed between protocol and 
publication in 40% to 62% of trials (28, 29). Finally, some discrepancies may exist between 
the real methods used and methods reported. Some deficiencies may appear simply because of 
poor reporting, which does not necessarily mean that the methods were not applied (30, 31). 
In fact, some details may not have been reported because the authors regarded them to be 
standard and not necessary to mention (e.g., radiographic view or details about film 
resolution). Similarly, authors are often forced by referees or editors to abbreviate the report, 
and so important information such as details on acquisition technique are removed from 
manuscripts. However, online appendices, supplemental information, or longer versions of a 
paper could be provided. For example, the U.S. Food and Drug Administration provided in its 
Website most of the required details of the radiographic methods used in reporting results of a 
trial.  
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In conclusion, our results have highlighted that the reporting of results of randomized 
controlled trials of radiographic outcomes measured by scheduled radiography in RA showed 
a great variability of radiographic scores used and that reporting of radiographic methods 
could be improved upon, especially the acquisition procedure and the reproducibility. 
Investigators are encouraged to follow guidelines on reporting radiographic data in 
randomized controlled trials in RA. 
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Figure 1. Process of screening articles on randomized controlled trials of radiographic 
outcomes in rheumatoid arthritis, for inclusion in the present analysis. 
 
 
Articles identified in Medline 
 
1004 articles 
 
77 articles selected 
927 articles excluded on the basis 
of title and abstract 
31 articles excluded after obtaining 
the full text 
   Extended follow up trials (n=13) 
   No radiographic outcome (n=5) 
   Subgroup analysis (n=6) 
   Cohort studies (n=4) 
   Nonrandomized trials (n=1) 
   Analysis of multiple trials (n=2) 
 
46 articles assessed 
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Table 1. Generic data on radiographs described in reports of randomized controlled trials of 
radiographic outcomes 
Generic data  N % 
   
Assessed areas 44/46 95.7 
   Hand and feet 33/44 75.0 
   Hand 9/44 20.402.3 
   Hand and ankle 1/44 02.3 
   Shoulders, elbows, hips, knees, ankles and subtalar joints 1/44 02.3 
   
Number of radiographic sessions 46/46 100.0 
   Baseline and 1 radiograph 20/46 43.5 
   Baseline and 2 radiographs 18/46 39.1 
   Baseline and 3 or more radiographs 8/46 17.4 
   
Radiographic view reported 11/46 23.9 
   Posteroanterior (e.g., dorsovolar for hands) 4/11 36.4 
   Anteroposterior 5/11 45.5 
   Both 2/11 18.1 
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Table 2. Radiographic outcomes in randomized controlled trials in rheumatoid arthritis 
 
Radiographic outcomes N=46 % 
   
Sharp score (original (32), modified by Sharp (33) or by van der Heijde’s (34, 
35)) 
22 47.8 
Erosion score and joint space narrowing score reported with composite score 16 34.8 
Larsen score (original (36, 37) or modified version (38)) 18 39.0 
Number of eroded joints counts 9 19.6 
Erosion score and joint space narrowing score reported without composite 
score 
5 10.9 
Number of erosions 3 06.5 
Ratingen score (39) 2 04.3 
Cumulative number of joints free of erosions at baseline in which at least one 
erosion developed during follow-up 
2 04.3 
Genant scoring method (40) 1 02.2 
Others 7 15.2 
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Table 3. Reporting of radiographic assessment in reports of randomized controlled trials with 
radiographic outcomes in rheumatoid arthritis
* 
 
 
 
 
 
 
Reporting of 
 
 
 
 
All 
N=46 
Reports with 
radiographic 
outcome as 
primary 
endpoint 
N=26 
Reports with 
radiographic 
outcome not 
as primary 
endpoint 
N=20 
 
 
Reports  
published  
before 2000 
N=17 
 
Reports  
published  
in 2000 and 
later 
N=29 
      
Reader’s information 71.7 73.1 70.0 70.6 72.4 
  Experience 36.9 34.6 40.0 35.3 64.7 
  Background  54.4 57.7 50.0 52.9 55.2 
  Identity 50.0 50.0 50.0 52.9 48.3 
      
Number of readers 91.3 96.2 85.0 94.1 89.7 
   1 26.1 19.2 35.0 29.4 24.2 
   >1 65.2 76.9 50.0 64.7 65.5 
   Not reported 08.7 03.9 15.0 05.9 10.3 
      
Blinding 93.5 96.2 90.0 94.1 93.1 
  To treatment or 
patient identity 
86.0 92.0 77.8 87.5 85.2 
  To clinical data 23.9 26.9 20.0 17.6 27.6 
      
How films were 
viewed 
 
73.9 
 
80.7 
 
65.0 
 
70.6 
 
75.9 
      
Reproducibility 39.1 53.8 20.0 35.3 41.4 
      
*
All data are expressed as percentages. 
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Appendix A. Journals included in the search strategy for randomized controlled trials with 
radiographic outcomes in rheumatoid arthritis 
 
10 general and internal medicine journals (New England Journal of Medicine, Journal of the 
American Medical Association, The Lancet, Annals of Internal Medicine, Annual Review of 
Medicine, Archives of Internal Medicine, British Medical Journal, American Journal of 
Medicine, Medicine, and Proceedings of the Association of American Physicians);  
6 rheumatologic journals (Arthritis and Rheumatism, Seminars in Arthritis and Rheumatism, 
Annals of Rheumatic Diseases, Rheumatology [Oxford, England], Journal of Rheumatology, 
and Arthritis Care and Resarch);  
6 orthopedic journals (Osteoarthritis and Cartilage/OARS, Arthroscopy, Journal of 
Orthopeadic Research: Official Publication of the Orthopaedic Research Society, Journal of 
Bone and Joint Surgery, American Volume, Spine, and Gait & Posture);  
6 rehabilitation journals (Archives of Physical Medicine and Rehabilitation, Supportive Care 
in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer, 
Journal of Electromyography and Kinesiology: Official Journal of the International Society 
of Electrophysiological Kinesiology, Physical Therapy, Journal of Rehabilitation Research 
and Development, and Scandinavian Journal of Rehabilitation Medicine).  
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